quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 5, 2026

LLY Up 28% in 3 Months: Is it the Right Time to Invest in the Stock?

View original at finance.yahoo.com
LLY Up 28% in 3 Months: Is it the Right Time to Invest in the Stock? Eli Lilly and Company’s LLY stock has risen 28% in the past three months…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Eli Lilly plans to file regulatory applications for orforglipron in type II diabetes in the first half of 2026

    80% confidence

  • Despite NVO having the lead in the oral obesity market, Lilly may be able to close the gap fast once orforglipron is approved by the FDA in 2026

    80% confidence

  • Eli Lilly expects new drugs (Mounjaro, Zepbound, Omvoh, Jaypirca, Ebglyss and Kisunla), along with expanded use of existing drugs, to drive sales growth in 2026

    80% confidence

  • Novo Nordisk will advance next-generation obesity candidate amycretin into late-stage development, both as injection and oral pill, with phase III program planned to initiate during first quarter of 2026

    80% confidence

  • Mounjaro and Zepbound account for more than 50% of the company's total revenues

    80% confidence

  • Eli Lilly is a great stock to have in one's portfolio, given its significant price appreciation, product and pipeline portfolio, robust growth prospects and bullish analyst sentiment

    80% confidence

  • Eli Lilly is a Zacks Rank #1 (Strong Buy) stock

    80% confidence

  • Mounjaro and Zepbound are expected to continue to see strong demand in 2026

    80% confidence

  • Structure Therapeutics expects to initiate late-stage program of aleniglipron in obesity around mid-2026

    80% confidence

  • Novo Nordisk expects to launch the Wegovy pill in early January 2026

    80% confidence

  • Eli Lilly expects data readouts from three phase III studies on retatrutide for treating obesity in the second half of 2026

    80% confidence

  • The obesity market is huge and multiple players can co-exist

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
LLY Up 28% in 3 Months: Is it the Right Time to Invest in the Stock? — Source | Via News | pt.VIA.NEWS